Etanercept-induced injection site reactions: Potential pathomechanisms and clinical assessment

Expert Opinion on Drug Safety

Volumn 11, Issue 6, 2012, Pages 911-921

  Batycka Baran, Aleksandra ^a,b   Flaig, Michael ^a   Molin, Sonja ^a   Ruzicka, Thomas ^a   Prinz, Joerg C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anti drug antibodies; Etanercept; Immunogenicity; Injection site reaction

Indexed keywords

ADALIMUMAB; CETIRIZINE; ETANERCEPT; PREDNISONE;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ARTHUS PHENOMENON; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHOCYTIC INFILTRATION; PATHOPHYSIOLOGY; PRURITUS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SKIN TEST; TREATMENT DURATION; URTICARIA;

ANTIBODY FORMATION; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN TESTS;

EID: 84867790251     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.727796     Document Type: Review

References (52)

1. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
2. Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf 2012;11:121-39
3. Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32:277-9
4. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2011;11:1-5
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
6. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
7. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
8. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26
9. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85
10. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51
11. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
12. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
13. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
14. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
15. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
16. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein. Arch Dermatol 2001;137:893-9
17. Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007;3:245-58
18. Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-associated injection-site reactions. Arch Dermatol 2000;136:556-7
19. Available from: http://www.ncbi.nlm.nih. gov/sites/entrez
20. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15
21. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34:19-22
22. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63
23. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6
24. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9
25. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5
26. Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32:672-4
27. Edwards KR, Mowad CM, Tyler WB. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol 2003;2:184-7
28. Papadavid E, Makris M, Dalamaga M, et al. Recall injection-site reactions to etanercept in a patient with psoriasis. Clin Exp Dermatol 2009;34:414-15
29. Rajakulendran S, Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology (Oxford) 2004;43:1588-9
30. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 2006;142:218-20
31. Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008;63:138-9
32. Bavbek S, Aydin O, Ataman S, et al. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011;66:1256-7
33. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61:912-20
34. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003;18:1257-9
35. Sauerborn M, Schellekens H. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? Curr Opin Biotechnol 2009;20:715-21
36. Christen U, Thuerkauf R, Stevens R, Lesslauer W. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol 1999;60774-90
37. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4
38. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999;131:634
39. Misery L, Perrot JL, Gentil-Perret A, et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002;146:334-5
40. Silver J, Benacerraf B. Dissociation of T cell helper function and delayed hypersensitivity. J Immunol 1974;113:1872-5
41. Nydegger UE. Immune complex pathophysiology. Ann N Y Acad Sci 2007;1109:66-83
42. Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt's essential immunology. Wiley-Blackwell; Oxford: 2011
43. Norman MU, Lister KJ, Yang YH, et al. TNF regulates leukocyte-endothelial cell interactions and microvascular dysfunction during immune complex-mediated inflammation. Br J Pharmacol 2005;144:265-74
44. Kohl J, Gessner JE. On the role of complement and Fc gamma-receptors in the Arthus reaction. Mol Immunol 1999;36:893-903
45. Orito H, Fujimoto M, Ishiura N, et al. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. J Leukoc Biol 2007;81:1197-204
46. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000;18:533-4
47. Delves PJ, Roitt IM. Encylopedia of immunology. Academic Press; London: 1998
48. Jacysyn JF, Abrahamsohn IA, Macedo MS. Modulation of delayed-type hypersensitivity during the time course of immune response to a protein antigen. Immunology 2001;102:373-9
49. Askenase PW, Atwood JE. Basophils in tuberculin and "Jones- Mote" delayed reactions of humans. J Clin Invest 1976;58:1145-54
50. Richerson HB, Dvorak HF, Leskowitz S. Cutaneous basophilic hypersensitivity: a new interpretation of the Jones-Mote reaction. J Immunol 1969;103:1431-4
51. Kopf M, Abel B, Gallimore A, et al. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002;8:373-8
52. Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J 2009;102:304-5